	Chemoresistance in cutaneous melanoma: contemporary and future aspects. Chin Clin Oncol Nigam S, Enshaie E, Smith J, Rai V. PMID: 40575971 [PubMed - indexed for MEDLINE]
	Efficacy, Safety, and Patient Reported Outcomes of Rhenium-Skin Cancer Therapy for Non-Melanoma Skin Cancer: 1-Year Results from the EPIC-Skin Study. Adv Radiat Oncol Cardaci G, Baxi S, Vohra S, Allison C, Hong A, Mulholland N, Sathekge M, Mokoala K, Heuschkel M, Tietze J, Mirzaei S, Dahlhoff G. PMID: 40575594 [PubMed]
	Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients. Vaccines (Basel) Broderick JC, Adams AM, Barbera EL, Van Decar S, Clifton GT, Peoples GE. PMID: 40573987 [PubMed]
	Metabolic Reprogramming in Melanoma: An Epigenetic Point of View. Pharmaceuticals (Basel) Giuliani S, Accetta C, di Martino S, De Vitis C, Messina E, Pescarmona E, Fanciulli M, Ciliberto G, Mancini R, Falcone I. PMID: 40573249 [PubMed]
	Comparing 2Â cm vs. 1Â cm surgical margins in acral melanoma of the sole with Breslow thickness greater than 2Â mm: A multicenter retrospective study of 336 Japanese patients. Eur J Surg Oncol Koizumi S, Yamazaki N, Ichigozaki Y, Kitagawa H, Kiniwa Y, Sato S, Takai T, Doi R, Ito T, Yasuda M, Kuwatsuka Y, Maekawa T, Asai J, Miyagawa T, Matsushita S, Funakoshi T, Yamamoto Y, Inozume T, Kishi A, Takenouchi T, Kokubu H, Ito S, Nakamura Y. PMID: 40570594 [PubMed - as supplied by publisher]
	Pembrolizumab-related toxicity in patients with advanced melanoma. N Z Med J de Roo F, Singh A, Zheng E, Tan A, Wong ANM. PMID: 40570335 [PubMed - indexed for MEDLINE]
	Correction to: Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study. Int J Clin Oncol Fujisawa Y, Yoshikawa S, Takenouchi T, Mori S, Asai J, Uhara H, Ichigosaki Y, Fujimura T, Nakamura Y, Nakamura Y, Ohno F, Fukumoto T, Ozawa T, Namikawa K, Sugihara S, Hoashi T, Shimauchi T, Sawada Y, Iwata H, Maeda T, Miyagawa T, Shibayama Y, Hatta N, Kishi A, Ishikawa M, Kawahira H, Katoh N, Okuyama R. PMID: 40569523 [PubMed - as supplied by publisher]
	Serum gp100 as an Independent Prognostic Biomarker in Early-Stage Uveal Melanoma. Invest Ophthalmol Vis Sci Bande MF, Piñeiro C, Lago-Baameiro N, Silva-Rodríguez P, Pardo M, Blanco-Teijeiro MJ. PMID: 40569116 [PubMed - indexed for MEDLINE]
	Comparison of 1-cm Versus 2-cm Excision Margins for Cutaneous Melanoma: A Systematic Review and Meta-Analysis. Cureus Pospyelova D, Bunola-Hadfield I, De La Cruz Monroy MF, Kandil MA, Fredericks-Bowyer LJ, Duvnjak H, Murdeshwar H, Rahman S. PMID: 40568274 [PubMed]
	Nutrition and Diet Patterns as Key Modulators of Metabolic Reprogramming in Melanoma Immunotherapy. J Clin Med Grafanaki K, Maniatis A, Anastogianni A, Bania A, Pasmatzi E, Stathopoulos C. PMID: 40565936 [PubMed]
	The Effectiveness of Group and Individual Training in Emotional Freedom Techniques for Patients in Remission from Melanoma: A Randomized Controlled Trial. Healthcare (Basel) Lazarov A, Church D, Shidlo N, Benyamini Y. PMID: 40565447 [PubMed]
	A Consolidated Review of Contemporary Targeted and Immunotherapeutic Options for Melanoma. Biomedicines Champion PJ, Bluestein JR, Quinn AE, Bell SD, Kiley JH, Wakefield MR, Fang Y. PMID: 40564107 [PubMed]
	Variation in Immune and Inflammatory Blood Markers in Advanced Melanoma Patients Treated with PD-1 Inhibitors: A Preliminary Exploratory Study. Biomedicines Bolovan LM, Panait ME, Busca A, Stanciu AE, Chiriac D, Mihalcea CE, Hotnog CM, Georgescu MT, Voinea SC, Prunoiu VM, Brasoveanu LI, Gales LN. PMID: 40564098 [PubMed]
	Disparities in Acral Lentiginous Melanoma: Racial Factors Beyond Delayed Diagnosis. J Am Acad Dermatol Grant S, Revan D, Tang L, Attwood K, Skitzki J, Paragh G. PMID: 40562077 [PubMed - as supplied by publisher]
	Review Article: Fecal Microbiota Transplantation in Melanoma: Mechanisms-Mediated Enhancement of Anti-Tumor Immunotherapy. Crit Rev Oncog Ung W, Bonavida B. PMID: 40561430 [PubMed - indexed for MEDLINE]
	Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301). J Clin Oncol Diab A, Ascierto PA, Maio M, Abdel-Wahab R, Negrier S, Mortier L, Arenberger P, Dalle S, Krajsova I, Cruz L, Leccia MT, Guida M, Lebbe C, Grob JJ, Butler MO, In GK, Loquai C, Walker JWT, Atkinson V, Kapiteijn E, Haferkamp S, Chunduru S, Rahimian S, Guidoboni M, Robert C. PMID: 40561410 [PubMed - as supplied by publisher]
	Germline Non-CDKN2A Variants in Melanoma and Associated Hereditary Cancer Syndromes. Diseases Fiasconaro CA, Carbone A, Giordano S, Cavallo F, Fava P, Pasini B, Yakymiv Y, Marchisio S, Quaglino P, Ribero S, Roccuzzo G. PMID: 40558591 [PubMed]
	Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study. Melanoma Res Pandit-Taskar N, Mauguen A, Frosina D, Jungbluth A, Busam KJ, Lyashchenko S, Schwartz J, Momtaz P, Warner AB, Smithy JW, Shoushtari AN, Callahan MK, Chapman PB, Postow MA. PMID: 40557547 [PubMed - as supplied by publisher]
	Artificial intelligence in melanoma diagnosis: ethical considerations and clinical implementation. Proc (Bayl Univ Med Cent) Verma KK, Grabow KM, Koch RS, Friedmann DP, Tarbox MB. PMID: 40557199 [PubMed]
	MYO1G promoter hypomethylation correlates with its mRNA expression, lymphocyte infiltration, and immunotherapy response in melanoma. Front Oncol Xia Y, Zhang Y, Zheng C, Wang J, Di W, Zhang M, Yang M. PMID: 40556672 [PubMed]

Articles 1 - 20 / 43000

Page 1 of 2150



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy